

**MEDIA CONTACT:****Gilead Sciences**

Venus TSANG

Venus.tsang@gilead.com

**World Hepatitis Alliance**

James GILLIES

james.gillies@worldhepatitisalliance.org

**GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS ON US\$4 MILLION GRANT FOR COMMUNITY LED INITIATIVES TO ACHIEVE VIRAL HEPATITIS ELIMINATION BY 2030**

*– World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee–*

*– Gilead Expands ALL4LIVER Grant to Support 71 Organizations Across Africa, South America, Asia and Oceania, Europe and North America–*

*–Community-Driven Initiatives Funded by ALL4LIVER Grant To Be Spotlighted At World Hepatitis Summit –*

**Lisbon, Portugal [8 April 2024]** – Gilead Sciences, Inc. (Nasdaq: GILD), announced today a global distribution of US\$4 million through its ALL4LIVER Grant (“Grant”) to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV).

Experience and learning of community organizations in Australia, Nigeria, Portugal, and Indonesia, supported by Gilead's ALL4LIVER Grant, will be showcased at the World Hepatitis Summit (“Summit”). The Summit is organized by the World Hepatitis Alliance, scheduled to take place in Lisbon from Apr. 9 – 11, 2024.

Gilead will host a symposium titled “Partnering for Global Health Equity: Case Studies from Around the World” at the Summit. This symposium aims to highlight the importance of collaborative partnerships in ensuring individuals living with hepatitis receive the care and services they deserve and spotlight the significance of empowering patient and community in the global fight against viral hepatitis.

Initially introduced in 2021 to target chronic hepatitis B in the Asia Pacific region, the biennial ALL4LIVER grant has now expanded into a global initiative (outside of the United States) to accelerate actions toward eliminating viral hepatitis. The World Hepatitis Alliance, joining other global experts on an independent review committee, extends its longstanding partnership with Gilead to further the Grant’s ambition of supporting community-led efforts and catalyzing viral hepatitis elimination efforts.

Rachel Halford, President of the World Hepatitis Alliance emphasized, "By harnessing the power of people and communities affected by viral hepatitis, we can accelerate action towards elimination. Gilead's ALL4LIVER initiative exemplifies the strength of collaborative efforts in our battle against viral hepatitis. Public-private partnerships are integral to achieving our shared goal of a world free from hepatitis."

The 2023 Gilead ALL4LIVER Grant focuses on empowering communities and fostering partnerships to tackle stigma and discrimination, while simultaneously promoting awareness of testing and emphasizing the urgency of viral hepatitis elimination targets on the public health agenda.

In Portugal, Grupo de Ativistas em Tratamento has been awarded a grant to improve awareness and scale up detection for vulnerable groups at risk of hepatitis C and hepatitis D through community-based testing programs. Similarly, in Nigeria, Centre for Initiative and Development Taraba has been granted resources to pioneer initiatives that improve disease awareness, testing for pregnant women and relink the diagnosed people of hepatitis B and hepatitis C to access of treatment.

"Stigma and discrimination of hepatitis are often caused by misunderstandings about how hepatitis is transmitted, and it can affect the everyday lives of people living with hepatitis and impact their willingness to seek help. Tackling viral hepatitis therefore requires a whole-of-society approach, from disease awareness and prevention, early diagnosis and access to health services, treatment, to addressing stigma and discrimination so these interventions are made possible and contribute to achieve the WHO's 2030 goals of eliminating viral hepatitis as a serious public health issue", said Luís Mendão, Grupo de Ativistas em Tratamento. "Community-driven initiatives empower us to address these pivotal challenges and yield meaningful results. Our goal is not just to offer immediate solutions but to cultivate sustainable support for people with lived experience."

"We're proud to partner with the World Hepatitis Alliance at global events like the Summit, highlighting community projects and our ongoing commitment to partner with the community in creating healthier futures for all individuals living with liver disease. In the global pursuit of prioritizing patient-centric care, Gilead Sciences is honored to lead endeavors tackling fundamental obstacles impeding elimination initiatives. The augmented grant and heightened financial support underscore our steadfast dedication to nurturing innovative solutions, empowering communities, and actively supporting the ambitious aim of eradicating viral hepatitis by 2030," said Alex Kalomparis, Senior Vice President of Public Affairs, Gilead Science.

For more information about Gilead ALL4LIVER Grant and former grantees, please visit <https://www.gileadall4liver.com/>

### **About World Hepatitis Alliance**

The World Hepatitis Alliance (WHA) is a patient-led and patient driven non-governmental organisation. With 320-member patient groups from over 100 countries, WHA works with governments, national members and other key partners to raise awareness of viral hepatitis and influence global change. To achieve a world free from viral hepatitis, WHA provides global leadership in advocacy, awareness-raising and the fight to end its social injustice.

### **About Gilead Sciences**

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

### **About the ALL4LIVER Grant**

Gilead Sciences launched the ALL4LIVER Grant in 2021, a biennial grant designed to empower local communities and the fight against viral hepatitis. The ALL4LIVER Grant program aims to support projects initiated by local communities in Africa, South America, Asia and Oceania, Europe, and North America (excluding the United States) to work towards the WHO goal of eliminating viral hepatitis as a public health threat by 2030.

###

*For more information on Gilead Sciences, please visit the company's website at [www.gilead.com](http://www.gilead.com), follow Gilead on X (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-30.*